Business
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, HOPE-2 Final Data Submitted for Publication- CAP-1002 – Capricor’s Cell Therapy Program for COVID-19 -Phase II INSPIRE Trial Enrollment Nearing Completion- Capricor’s Exosomes Platform Technology-Positioning Multivalent Exosome-mRNA Vaccine as Booster to Currently Available Vaccines- -Completing Non-Clinical Studies for IND Submission- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results for the second quarter ended June 30, 2021, and provided an overview of its recent operational highlights. Management will host a webcast and conference call at 4:30 p.m. Eastern Time today. “This has been a productive quarter for Capricor and I am pleased to report our progress across the organization as we have a busy back half of 2021 planned. We now have a clear path forward with CAP-1002 for DMD as we prepare to initiate a pivotal study later this year. The final data has been submitted for publication which shows that CAP-1002 has a significant impact on skeletal and cardiac muscle function in late-stage DMD patients, which we believe will further support the clinical path to potential approval. The positive momentum of this program has continued to advance our partnering discussions. Additionally, we have made progress in our exosome program, by expanding our team with seasoned biotechnology leaders who bring a wealth of experience in engineering exosomes for therapeutic use. We are now moving our multivalent exosome-mRNA vaccine towards the clinic, designed to be a booster to currently available vaccines. We believe that this multiple protein approach could potentially confer greater immune protection against variants of SARS-CoV-2,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “Lastly, we have seen enrollment of our INSPIRE clinical trial for treating severe COVID-19 patients increase with the emerging prevalence of the Delta v...